Whitehawk Therapeutics Inc. (WHWK)
NASDAQ: WHWKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:18 AM ET
WHWK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $193.83M
- EPS (TTM)
- -$1.14
- Dividend yield
- None
- 52-week range
- 1.87 – 5.50
- Day range
- 3.33 – 3.43
- Volume / Avg
- 26.82K / 371.36K
- Beta
- —
- Shares outstanding
- 57.01M
- Next earnings
- Nov 5, 2026
52-week range
WHWK stock today
On Oct 8, WHWK is trading at $3.40, shedding $0.01 (0.29%), versus the S&P 500's 0.39% decline. Shares are 38.1% below their 52-week high of $5.50, set on May 14, 2026 and 81.8% above the 52-week low of $1.87, in the middle of the past year's range. WHWK is up 40.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 53.6%.
Whitehawk Therapeutics has posted a net loss over the last twelve months (EPS of -$1.14), so its P/E ratio is not meaningful. Whitehawk Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Whitehawk Therapeutics
Company profileWhitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David J. Lennon Ph.D.
- Headquarters
- Morristown, NJ
- Employees
- 32
- Website
- ir.whitehawktx.com
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$7.71+126.76%
- Strong buy 1
- Buy 5
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.26
Whitehawk Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELDNEledon Pharmaceuticals Inc. | 2.39 | -1.45% | $193.81M | vs WHWK |
| NGENNervGen Pharma Corp. | 1.80 | +3.16% | $193.00M | vs WHWK |
| ADCTADC Therapeutics SA | 1.54 | +8.42% | $196.61M | vs WHWK |
| RNACCartesian Therapeutics Inc. | 6.72 | +0.60% | $203.32M | vs WHWK |
| ADAGAdagene Inc. ADR | 2.74 | -2.49% | $183.97M | vs WHWK |
| LYELLyell Immunopharma Inc. | 8.39 | -1.99% | $205.60M | vs WHWK |
| YARWYarrow Bioscience Inc. | 19.15 | +2.00% | $178.18M | vs WHWK |
| TRDAEntrada Therapeutics Inc. | 5.47 | -2.50% | $212.98M | vs WHWK |
Indexes, lists and sector
Whitehawk Therapeutics stock FAQ
What is Whitehawk Therapeutics's stock price today?
WHWK last traded at $3.40 as of Oct 8, 11:18 AM EDT, down 0.29% on the day. Prices are delayed at least 15 minutes.
Does Whitehawk Therapeutics pay a dividend?
No. Whitehawk Therapeutics does not currently pay a regular cash dividend.
When is Whitehawk Therapeutics's next earnings date?
Whitehawk Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.26.
Who is Whitehawk Therapeutics's CEO?
Dr. David J. Lennon Ph.D. is the chief executive officer of Whitehawk Therapeutics Inc., which has about 32 employees.
Has WHWK ever split its stock?
Yes. The most recent WHWK stock split was a 1-for-15 split on Aug 27, 2021.
What is the WHWK 52-week high?
The 52-week high for WHWK is $5.50 and the 52-week low is $1.87. The stock is currently 38.1% below its high.